April 25, 2024 22:17 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Neither shocked nor surprised': Mallikarjun Kharge writes open letter to PM Modi over Congress manifesto row | 'Biased, reflects poor understanding': India dumps US report on alleged rights abuse | Lok Sabha Elections 2024: ECI issues notices to BJP, Congress on complaints against Modi, Rahul | Massive landslide hits Arunachal Pradesh, a large section of Highway-33 washed away | Actress Tamannaah Bhatia summoned by Maharashtra cyber cell in 2023 illegal IPL streaming case
Pfizer launches pilot COVID-19 vaccine distribution preparedness program in 4 US states Pfizer
Image: Wikimedia Commons

Pfizer launches pilot COVID-19 vaccine distribution preparedness program in 4 US states

India Blooms News Service | @indiablooms | 17 Nov 2020, 04:44 pm

Moscow/Sputnik: US pharmaceutical company Pfizer announced in a press release on Tuesday it was launching a pilot program that aims to inform the delivery and distribution of its coronavirus vaccine in the US states of Rhode Island, Texas, New Mexico and Tennessee.

"To build on our coordination with the relevant U.S. agencies, Pfizer launched this pilot program to help better support the states’ planning, deployment, and administration of the COVID-19 vaccine candidate. Learnings from this program will be adapted for usage across other states to help them create effective immunization programs for this vaccine," the company said in a press release.

According to Pfizer, the four US states were selected due to their differences in overall size, diversity of populations, and immunization infrastructure, as well as the need to reach populations both in rural and urban areas.

In a disclaimer of future preferential benefits for these four states, the company has stressed that they "will not receive vaccine doses earlier than other states by virtue of this pilot, nor will they receive any differential consideration."

Pfizer developed the vaccine in collaboration with German biotechnology company BioNTech. As the unregistered vaccine is underway with phase 3 clinical trials, the creators have declared above 90-percent efficiency.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.